These data indicate that simultaneous inhibition of WNT5A and RhoA signaling is a more effective strategy for hindering tumor cell invasion of BRAF wild‐type and BRAFV600 mutated melanomas treated with a BRAF inhibitor than targeting either WNT5A or RhoA individually. This evidence concerns the gene BRAF and melanoma.